Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hippo-YAP Pathway and Related miRNAs in Preterm Birth (HIPPO-PTB)

8. juli 2026 oppdatert av: Nazan Yurtcu MD, Cumhuriyet University

Analysis of Hippo-YAP Pathway Genes and Proteins and Related miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375 Expression in Maternal Blood, Placental Tissue, and Myometrial Tissue From Women With Term and Preterm Cesarean Delivery

This completed observational study evaluated the expression of Hippo-YAP pathway-related genes and proteins and selected microRNAs in maternal blood, placental tissue, and myometrial tissue obtained from women who underwent cesarean delivery at term or preterm gestational ages.

The study compared women with spontaneous preterm delivery and women with term delivery. Maternal blood, placental tissue, and myometrial tissue samples were analyzed using molecular, biochemical, and immunohistochemical methods to explore whether Hippo-YAP pathway activity and related miRNA expression patterns may be associated with the pathophysiology of preterm birth.

Studieoversikt

Detaljert beskrivelse

Preterm birth remains an important obstetric condition associated with neonatal morbidity and mortality. Although clinical risk factors for preterm birth are well described, the underlying molecular mechanisms are not fully understood. Inflammation, immune regulation, placental function, and myometrial activity are considered important components of the biological processes leading to preterm labor and delivery.

The Hippo-YAP signaling pathway is involved in cellular proliferation, differentiation, tissue homeostasis, immune regulation, and placental biology. Several microRNAs are also known to regulate reproductive tissues, placental function, myometrial activity, and inflammatory pathways. Based on this biological background, this study investigated the Hippo-YAP pathway and selected related microRNAs in maternal blood, placental tissue, and myometrial tissue from women with term and preterm cesarean delivery.

This was a completed observational case-control biomarker study. Participants were not assigned to any intervention. The study included two groups: women who delivered preterm and women who delivered at term. Maternal blood samples were collected before cesarean delivery. Placental tissue samples were obtained after delivery, and myometrial tissue samples were collected from the placental bed during cesarean section. Samples were stored under appropriate laboratory conditions until analysis.

The study evaluated the expression of Hippo-YAP pathway-related genes and proteins, including MST1, LATS1, YAP1, TAZ, MAP4K1, and PIK3C2B, as well as selected related microRNAs, including miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375. Gene and microRNA expression analyses were performed using quantitative real-time polymerase chain reaction. Protein expression was assessed using enzyme-linked immunosorbent assay and immunohistochemistry.

The primary objective was to compare Hippo-YAP pathway-related gene, protein, and microRNA expression patterns between preterm and term delivery groups. Secondary objectives included evaluating expression patterns across maternal blood, placental tissue, and myometrial tissue and exploring whether these molecular differences may contribute to understanding the biological mechanisms involved in preterm birth.

The study was approved by the Sivas Cumhuriyet University Clinical Research Ethics Committee. Written informed consent was obtained from participating women. The project was supported by the Scientific and Technological Research Council of Türkiye (TUBITAK), project number 121S414, and the immunohistochemistry experiments were additionally supported by a complementary research grant, project number T-2022-954-D7.

This study was retrospectively registered after completion of participant enrollment, sample collection, and laboratory analyses for transparency.

Studietype

Observasjonsmessig

Registrering (Faktiske)

44

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Kayseri Ave
      • Sivas, Kayseri Ave, Tyrkia (Türkiye), 58140
        • Sivas Cumhuriyet University Faculty of Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Pregnant women who underwent cesarean delivery at Sivas Cumhuriyet University Faculty of Medicine and were included in either the spontaneous preterm delivery group or the term delivery comparison group.

Beskrivelse

Inclusion Criteria:

- cInclusion Criteria:

  • Pregnant women aged 18 years or older
  • Singleton pregnancy
  • Women who underwent cesarean delivery
  • For the preterm delivery group: spontaneous preterm labor and delivery between 24 and 34 weeks of gestation
  • For the term delivery group: cesarean delivery at term gestational age without active labor
  • Written informed consent for participation and collection of maternal blood, placental tissue, and myometrial tissue samples

Exclusion Criteria:

  • Multiple pregnancy
  • Major fetal anomaly
  • Clinical evidence of chorioamnionitis
  • Hypertensive disorders of pregnancy
  • Diabetes mellitus or gestational diabetes mellitus
  • Autoimmune disease
  • Chronic inflammatory disease
  • Maternal systemic infection
  • Placental abruption
  • Premature rupture of membranes, if excluded in the original protocol
  • Use of medications or presence of maternal conditions that could significantly affect inflammatory, molecular, or placental biomarker expression
  • Refusal to provide informed consent

Exclusion Criteria:

-

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Preterm Delivery Group
Women who underwent cesarean delivery between 24 and 34 weeks of gestation after spontaneous preterm labor. Maternal blood, placental tissue, and myometrial tissue samples were collected for molecular, biochemical, and immunohistochemical analyses.
Laboratory analysis of maternal blood, placental tissue, and myometrial tissue samples for Hippo-YAP pathway-related gene, protein, and microRNA expression. No treatment or clinical intervention was assigned to participants.
Term Delivery Group
Women who underwent cesarean delivery after 39 weeks of gestation without active labor. Maternal blood, placental tissue, and myometrial tissue samples were collected as the term delivery comparison group.
Laboratory analysis of maternal blood, placental tissue, and myometrial tissue samples for Hippo-YAP pathway-related gene, protein, and microRNA expression. No treatment or clinical intervention was assigned to participants.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Expression levels of Hippo-YAP pathway-related genes, proteins, and selected microRNAs
Tidsramme: Perioperative/Periprocedural
Expression levels of Hippo-YAP pathway-related genes and proteins, including MST1, LATS1, YAP1, TAZ, MAP4K1, and PIK3C2B, and selected microRNAs, including miRNA-195, miRNA-181c, miRNA-200a, and miRNA-375, were compared between women with preterm delivery and women with term delivery using maternal blood, placental tissue, and myometrial tissue samples.
Perioperative/Periprocedural

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Tissue-specific expression patterns of Hippo-YAP pathway biomarkers and related microRNAs
Tidsramme: Perioperative/Periprocedural
Expression patterns of Hippo-YAP pathway-related genes, proteins, and selected microRNAs were evaluated across maternal blood, placental tissue, and myometrial tissue samples to explore tissue-specific molecular differences between preterm and term delivery groups.
Perioperative/Periprocedural

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Nazan Yurtcu, MD, PhD, Cumhuriyet University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2021

Primær fullføring (Faktiske)

1. april 2024

Studiet fullført (Faktiske)

31. mai 2024

Datoer for studieregistrering

Først innsendt

2. juli 2026

Først innsendt som oppfylte QC-kriteriene

8. juli 2026

Først lagt ut (Faktiske)

10. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • TUBITAK-121S414
  • 121S414 (Annet stipend/finansieringsnummer: The Scientific and Technological Research Council of Türkiye (TÜBİTAK), 1002 Rapid Support Program)
  • T-2022-954 (Annet stipend/finansieringsnummer: Sivas Cumhuriyet University BAP)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared because no prospective data-sharing consent for public individual-level data sharing was obtained, and the dataset includes sensitive maternal clinical information and biological sample-related laboratory data.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere